Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F23%3A10459199" target="_blank" >RIV/00064203:_____/23:10459199 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/23:10459199

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=5GmZlkEAof" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=5GmZlkEAof</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41375-022-01770-3" target="_blank" >10.1038/s41375-022-01770-3</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

Popis výsledku v původním jazyce

For children with high-risk, first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL), allogeneic hematopoietic stem cell transplantation (alloHSCT) after achieving a second complete remission (CR) remains the best, potentially curative treatment. In addition, a minimal residual disease (MRD)-negative status at the end of consolidation is an important prognostic indicator as demonstrated in the Children&apos;s Oncology Group Studies AALL1131 (high risk) and AALL0932 (standard risk), and ALLR3 and ALL-REZ BFM 2002 studies. Blinatumomab, a CD3/CD19-directed bispecific T-cell engager (BiTE(R)) molecule, demonstrated a favorable benefit-risk profile prior to/after alloHSCT in patients with relapsed/refractory B-ALL in clinical trials and real-world experience studies, with early termination of enrollment in phase 3 trials in young adults and children because of blinatumomab benefit [4, 6]. In the phase 3 trial in pediatric high-risk, first-relapse B-ALL, blinatumomab consolidation pre-alloHSCT resulted in improved event-free survival (EFS) and MRD remission vs. chemotherapy, with EFS benefit consistently found in all subgroups, including those with extramedullary disease and very early relapse (&lt;18 months) [6]. Enrollment was terminated for EFS benefit of blinatumomab (p &lt; 0.001) per independent data monitoring committee&apos;s (DMC) recommendation based on the July 2019 datacut. Follow-up data presented here are from September 2021, with overall survival (OS) benefit becoming apparent with longer follow-up.

Název v anglickém jazyce

Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

Popis výsledku anglicky

For children with high-risk, first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL), allogeneic hematopoietic stem cell transplantation (alloHSCT) after achieving a second complete remission (CR) remains the best, potentially curative treatment. In addition, a minimal residual disease (MRD)-negative status at the end of consolidation is an important prognostic indicator as demonstrated in the Children&apos;s Oncology Group Studies AALL1131 (high risk) and AALL0932 (standard risk), and ALLR3 and ALL-REZ BFM 2002 studies. Blinatumomab, a CD3/CD19-directed bispecific T-cell engager (BiTE(R)) molecule, demonstrated a favorable benefit-risk profile prior to/after alloHSCT in patients with relapsed/refractory B-ALL in clinical trials and real-world experience studies, with early termination of enrollment in phase 3 trials in young adults and children because of blinatumomab benefit [4, 6]. In the phase 3 trial in pediatric high-risk, first-relapse B-ALL, blinatumomab consolidation pre-alloHSCT resulted in improved event-free survival (EFS) and MRD remission vs. chemotherapy, with EFS benefit consistently found in all subgroups, including those with extramedullary disease and very early relapse (&lt;18 months) [6]. Enrollment was terminated for EFS benefit of blinatumomab (p &lt; 0.001) per independent data monitoring committee&apos;s (DMC) recommendation based on the July 2019 datacut. Follow-up data presented here are from September 2021, with overall survival (OS) benefit becoming apparent with longer follow-up.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia

ISSN

0887-6924

e-ISSN

1476-5551

Svazek periodika

37

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

4

Strana od-do

222-225

Kód UT WoS článku

000895589500002

EID výsledku v databázi Scopus

2-s2.0-85143596062